Generic Musculoskeletal Disorders Drugs Market Report 2025

The generic musculoskeletal disorders drugs market size has grown strongly in recent years. It will grow from $0.06 billion in 2024 to $0.06 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to incidence of musculoskeletal disorders, regulatory environment, healthcare infrastructure development, patient awareness and education, economic factors.

The generic musculoskeletal disorders drugs market size is expected to see strong growth in the next few years. It will grow to $0.08 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to population growth and aging, emerging markets, precision medicine and personalized therapies, healthcare reforms, global health trends. Major trends in the forecast period include technological integration in treatment, government initiatives and healthcare policies, focus on pain management alternatives, increased adoption of biosimilars, advancements in generic drug development.

The significant prevalence of arthritis is anticipated to drive the growth of the generic musculoskeletal disorders drugs market in the coming years. Arthritis involves tenderness and swelling of the joints, accompanied by symptoms such as joint pain and stiffness. Generic musculoskeletal disorders drugs are designed to alleviate pain and stiffness in muscles and can effectively treat muscle spasms in arthritis patients. For instance, in March 2022, data published by Versus Arthritis, a UK-based charity, indicated that approximately 10 million individuals in the UK are diagnosed with osteoarthritis, which includes 5.4 million with knee OA and 3.2 million with hip OA. Additionally, around 450,000 people have rheumatoid arthritis and 190,000 have psoriatic arthritis, contributing to over 20 million individuals living with musculoskeletal conditions. This has resulted in more than 30 million prescriptions dispensed for these conditions at a cost of about £139 million in 2022-2023. Therefore, the high prevalence of arthritis is fueling the growth of the generic musculoskeletal disorders drugs market.

The increasing adoption of telemedicine is expected to further propel the growth of the generic musculoskeletal disorders drugs market. Telemedicine involves leveraging telecommunications and digital technologies to provide remote healthcare services, facilitating virtual consultations between patients and healthcare providers. The adoption of telemedicine enhances accessibility, convenience, and continuity of care for patients with musculoskeletal disorders. For instance, data from FAIR Health Inc. in April 2023 indicates a 7.3% increase in national telehealth use, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. Thus, the growing embrace of telemedicine contributes to the expansion of the generic musculoskeletal disorders drugs market.

Strategic partnerships emerge as a prominent trend in the generic musculoskeletal disorders drugs market, with companies entering partnerships to bolster their market positions. A notable example is the collaboration between Mitsubishi Tanabe Pharma Corporation, a Japanese pharmaceutical company, and Eli Lilly and Company, a U.S.-based pharmaceutical company, aimed at broadening product lines and providing effective treatments for conditions such as diabetes. Additionally, Pfizer Inc., a major pharmaceutical and biotechnology corporation, partnered with Alex Therapeutics, a Swedish digital therapeutics company, in February 2022, offering patients evidence-based, clinically verified, and tailored digital therapeutics through this strategic alliance.

Major companies operating in the generic musculoskeletal disorders drugs market are placing emphasis on innovative products to drive revenue growth. An example is the introduction of the non-permanent ossiofiber compression staple by Ossio Inc., a U.S.-based company specializing in orthopedic and musculoskeletal applications. This medical device, designed for fracture fixation and bone fusion in orthopedic surgeries, offers temporary stability and compression to promote bone healing and fusion. The non-permanent ossiofiber compression staple presents an alternative to traditional implants and permanent metal hardware.

In October 2023, Amgen Inc., a U.S.-based biopharmaceutical company, acquired Horizon Therapeutics Plc for $27.8 billion. This acquisition enables Amgen to diversify its product line and offer treatments for severe inflammatory, autoimmune, and rare disorders. Horizon Therapeutics Plc, an Ireland-based biopharmaceutical company, contributes to Amgen's commitment to utilizing biology to address life-threatening disorders.

Major companies operating in the generic musculoskeletal disorders drugs market include Pfizer Inc., Sanofi S.A., Eli Lilly and Company, Ampio Pharmaceuticals Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca plc, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc, Eisai Co. Ltd., Biogen Inc., Sino Biopharmaceutical Limited, Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bayer AG, Mylan Pharmaceuticals Inc., Taisho Pharmaceutical Holdings Co. Ltd., Flexion Therapeutics Inc.

Asia-Pacific was the largest region in the generic musculoskeletal disorders drugs market in 2024. The regions covered in the generic musculoskeletal disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the generic musculoskeletal disorders drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Generic musculoskeletal disorders drugs play a crucial role in managing conditions related to the musculoskeletal system, providing relief from pain, stiffness in muscles, and treating muscle spasms.

The main treatments for generic musculoskeletal disorders drugs include medication, therapy, surgery, and other interventions. Medications come in various forms, containing one or more active chemicals and potential inactive components. They can be administered through oral, parenteral, and other routes to address conditions such as osteoarthritis, rheumatoid arthritis, spondylarthritis, juvenile idiopathic arthritis, psoriatic arthritis, fibromyalgia, and other musculoskeletal disorders. These drugs are distributed through different channels, including hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

The generic musculoskeletal disorders drugs market research report is one of a series of new reports that provides generic musculoskeletal disorders drugs market statistics, including generic musculoskeletal disorders drugs industry global market size, regional shares, competitors with a generic musculoskeletal disorders drugs market share, detailed generic musculoskeletal disorders drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic musculoskeletal disorders drugs industry. This generic musculoskeletal disorders drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The generic musculoskeletal disorders drugs market consists of sales of analgesics, oral non-steroidal anti-inflammatory drugs (NSAIDs), opioids, anti-neuropathic pain medications, corticosteroids, and disease modifying anti-rheumatic drugs (DMARDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.